1. Johson & Johnson is embarking on a two-year restructuring process of its orthopedic business after its third quarter earnings report reflected a shortfall in medical device sales.
2. Johnson & Johnson posted increases in third quarter revenue and orthopedic sales.
3. DePuy Synthes, Johnson and Johnson’s orthopedic company, earned FDA 510(k) clearance for the TriALTIS spine system.
